ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
17 janv. 2024 08h30 HE
|
Elevai Labs Inc.
ELEVAI Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
16 janv. 2024 08h30 HE
|
Elevai Labs Inc.
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
02 janv. 2024 09h15 HE
|
Elevai Labs Inc.
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
11 déc. 2023 09h15 HE
|
Elevai Labs Inc.
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
ELEVAI Labs, Inc. Expands International Distribution into Europe
07 déc. 2023 09h41 HE
|
Elevai Labs Inc.
ELEVAI Labs, Inc. Expands International Distribution into Europe
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
29 nov. 2023 09h00 HE
|
Elevai Labs Inc.
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences
Nanomix Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy
29 nov. 2022 08h30 HE
|
Nanomix Corporation
SAN LEANDRO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care (POC)...
Nanomix Appoints Industry Veteran Tadd S. Lazarus, M.D., to the Board of Directors
31 août 2022 09h00 HE
|
Nanomix Corporation
SAN LEANDRO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics,...
Nanomix Receives CE Mark for its eLab COVID-19 Rapid Point-of-Care Antigen Panel
20 mai 2022 08h30 HE
|
Nanomix Corporation
EMERYVILLE, Calif, May 20, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCBB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics,...